Alector Inc (ALEC)

NASDAQ
26.81
+1.35(+5.30%)
After Hours
26.45
-0.36(-1.34%)
- Real-time Data
  • Volume:
    1,410,851
  • Bid/Ask:
    25.70/26.50
  • Day's Range:
    25.33 - 27.05

ALEC Overview

Prev. Close
25.46
Day's Range
25.33-27.05
Revenue
21.43M
Open
26.02
52 wk Range
9.12-43.32
EPS
-2.68
Volume
1,410,851
Market Cap
2.17B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,581,927
P/E Ratio
-
Beta
-
1-Year Change
90.55%
Shares Outstanding
80,875,423
Next Earnings Date
Nov 16, 2021
What is your sentiment on Alector Inc?
or
Market is currently closed. Voting is open during market hours.

Alector Inc News

Alector Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Alector Inc Company Profile

Alector Inc Company Profile

Sector
Services
Employees
184

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer’s disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer’s disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Read More
  • o.o
    0
    • Earnings this week 😍
      1
      • This will go up to where it belong. Strong buy
        0
        • 🚀🚀
          0
        • When?
          0
      • agreed
        0
        • they have a potential breakthrough alzheimer drug
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.